MiR-125b缺失激活HIF1α/pAKT环路导致肝细胞癌经动脉化疗栓塞抵抗
该研究利用4个独立肝细胞癌队列共680例患者,发现与辅助TACE后复发相关的41个miRNA特征,其中miR-125b在复发患者中降低最显著。机制上miR-125b缺失激活HIF1α/pAKT环路并富集CD24阳性TACE抵抗性癌症干细胞群。高CD24或EPO患者辅助TACE后预后差,TACE一线治疗前血EPO高与TACE反应差相关。
要点
- 肿瘤miR-125b低表达者辅助TACE后至复发时间显著缩短。
- miR-125b缺失通过HIF1α/pAKT环路及CD24阳性干细胞群介导TACE抵抗。
- 高CD24或EPO者辅助TACE后预后差,血EPO高与TACE反应差相关。
核心结论
- MiR-125b缺失激活HIF1α/pAKT环路,导致肝细胞癌对TACE抵抗。
- 该轴关键节点有潜力辅助肝细胞癌患者选择TACE治疗。
研究设计与样本
- 研究使用4个独立肝细胞癌队列共680例患者。
- 对患者进行微小RNA(miRNA)转录组分析。
- 体外和体内实验研究miR-125b缺失对HIF1α/pAKT环路的影响。
主要发现
- 在肝细胞癌患者中鉴定出与辅助TACE后复发相关的41个miRNA特征,miR-125b是复发患者中降低最显著的miRNA。
- 在两个独立队列中,肿瘤miR-125b低表达的肝细胞癌患者辅助TACE后至复发时间显著缩短。
- miR-125b缺失在体外和体内显著激活缺氧诱导因子1α亚基(HIF1α)/pAKT环路。
- miR-125b通过结合HIF1A内部核糖体进入位点区域并靶向YB-1直接减弱HIF1α翻译,并通过靶向PDGFβ受体阻断自分泌HIF1α/血小板衍生生长因子β(PDGFβ)/pAKT/HIF1α环路。
- miR-125b缺失/HIF1α轴诱导CD24和促红细胞生成素(EPO)表达并富集TACE抵抗的CD24阳性癌症干细胞群。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Transarterial chemoembolization (TACE) is a standard locoregional therapy for patients with hepatocellular carcinoma (HCC) patients with a variable overall response in efficacy. We aimed to identify key molecular signatures and related pathways leading to HCC resistance to TACE, with the hope of developing effective approaches in preselecting patients with survival benefit from TACE. APPROACH AND RESULTS: Four independent HCC cohorts with 680 patients were used. MicroRNA (miRNA) transcriptome analysis in patients with HCC revealed a 41-miRNA signature related to HCC recurrence after adjuvant TACE, and miR-125b was the top reduced miRNA in patients with HCC recurrence. Consistently, patients with HCC with low miR-125b expression in tumor had significantly shorter time to recurrence following adjuvant TACE in two independent cohorts. Loss of miR-125b in HCC noticeably activated the hypoxia inducible factor 1 alpha subunit (HIF1α)/pAKT loop in vitro and in vivo. miR-125b directly attenuated HIF1α translation through binding to HIF1A internal ribosome entry site region and targeting YB-1, and blocked an autocrine HIF1α/platelet-derived growth factor β (PDGFβ)/pAKT/HIF1α loop of HIF1α translation by targeting the PDGFβ receptor. The miR-125b-loss/HIF1α axis induced the expression of CD24 and erythropoietin (EPO) and enriched a TACE-resistant CD24-positive cancer stem cell population. Consistently, patients with high CD24 or EPO in HCC had poor prognosis following adjuvant TACE therapy. Additionally, in patients with HCC having TACE as their first-line therapy, high EPO in blood before TACE was also noticeably related to poor response to TACE. CONCLUSIONS: MiR-125b loss activated the HIF1α/pAKT loop, contributing to HCC resistance to TACE and the key nodes in this axis hold the potential in assisting patients with HCC to choose TACE therapy.
引用
- Wei X, Zhao L, Ren R, et al. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology. 2020. PMID: 32609900. doi:10.1002/hep.31448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。